Emerging Applications of Vitamin E TPGS in Drug Delivery
Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology, Trends in Formulation, October 2022
Volume 2022 eBook
Issue 3
Pages: 20–28
The author discusses some new applications of TPGS in the pharmaceutical field that should see this versatile excipient retain its place in the drug formulators toolbox.
Yuri Hoydas - Stock.adobe.com
Vitamin E TPGS, or d-α-tocopheryl polyethylene glycol 1000 succinate, was first developed more than 60 years ago as a water-soluble form of naturally occurring vitamin E. Originally used to treat vitamin E deficiency in cholestatic patients, TPGS quickly attracted attention as a versatile solubilizer due to its amphiphilic nature and surfactant properties. Further application of this molecule emerged in the 1990s, when TPGS was shown to improve epithelial absorption by modulating cellular efflux. Researchers have continued to find a variety of new and exciting applications of this molecule, and TPGS has become an important tool for drug delivery formulators. This report serves to summarize some of recent innovations using TPGS for improved delivery of bioactive materials.
Read this article in the Trends in Formulation ebook.
About the author
Greg Paddon-Jones, PhD, is director of Product Development at Antares Health Products.
Article details
Pharmaceutical Technology
eBook: Trends in Formulation
October 2022
Pages: 20–28
Citation
When referring to this article, please cite it as G. Paddon-Jones, "Emerging Applications of Vitamin E TPGS in Drug Delivery," Pharmaceutical Technology's Trends in Formulation eBook (October 2022).
Articles in this issue
Small is a Powerful Ingredient for Patient-Centric Formulations
Using a Drug Candidate Screening Strategy to Mitigate Late-Stage Risk
Addressing Developmental Challenges of Gene Therapy Viral Vectors
Improved Formulations to Enable Stable Delivery of Biologics
Nitrosamides–Should They Be Treated the Same as Nitrosamines?
Emerging Applications of Vitamin E TPGS in Drug Delivery
Recent Videos
Related Content
AAPS PharmSci 360 2024: Predictive Models for Poorly Soluble Drugs
October 10th 2024Article
Pharmaceutical Technology sat down with Niloufar Salehi, advisor at Eli Lilly & Company, to talk about the session she is moderating at AAPS PharmSci 360 2024, Symposium: An Accelerated Development of Poorly Soluble Drugs Using Predictive Tool.
